Login to Your Account



Allon Hammered as Davunetide Misses in a Pivotal PSP Trial

By Staff Reports


Tuesday, December 18, 2012
Shares of Canadian firm Allon Therapeutics Inc. lost 94 percent of their value Tuesday on news that the company's pivotal study of lead candidate davunetide failed to show an effect in patients with progressive supranuclear palsy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription